TRCT
PBYI icon

Tower Research Capital (TRC)’s Puma Biotechnology PBYI Stock Holding History

Tower Research Capital (TRC)’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.4K Buy
2,568
+329
+15% +$2.12K ﹤0.01% 3615
2025
Q4 		$13.3K Sell
2,239
-1,640
-42% -$8.71K ﹤0.01% 3415
2025
Q3 		$20.6K Sell
3,879
-4,590
-54% -$19.5K ﹤0.01% 3284
2025
Q2 		$29K Buy
8,469
+5,403
+176% +$17.2K ﹤0.01% 3424
2025
Q1 		$9.07K Sell
3,066
-7,071
-70% -$22.1K ﹤0.01% 3824
2024
Q4 		$30.9K Buy
10,137
+6,351
+168% +$18.5K ﹤0.01% 2881
2024
Q3 		$9.65K Buy
3,786
+3,751
+10,717% +$11.4K ﹤0.01% 3848
2024
Q2 		$114 Sell
35
-1,657
-98% -$7.28K ﹤0.01% 5476
2024
Q1 		$8.97K Sell
1,692
-1,110
-40% -$5.98K ﹤0.01% 3924
2023
Q4 		$12.1K Sell
2,802
-1,629
-37% -$5.4K ﹤0.01% 4072
2023
Q3 		$11.7K Buy
4,431
+4,396
+12,560% +$15K ﹤0.01% 3967
2023
Q2 		$124 Sell
35
-4,818
-99% -$15K ﹤0.01% 5795
2023
Q1 		$15K Sell
4,853
-9,897
-67% -$37.3K ﹤0.01% 3803
2022
Q4 		$63K Sell
14,750
-4,610
-24% -$15.9K ﹤0.01% 2167
2022
Q3 		$46K Buy
19,360
+1,427
+8% +$4.17K ﹤0.01% 3240
2022
Q2 		$52K Buy
17,933
+10,738
+149% +$26.7K ﹤0.01% 2844
2022
Q1 		$20K Sell
7,195
-1,394
-16% -$3.61K ﹤0.01% 3538
2021
Q4 		$26K Buy
8,589
+4,039
+89% +$17.5K ﹤0.01% 3393
2021
Q3 		$32K Buy
4,550
+161
+4% +$1.21K ﹤0.01% 3316
2021
Q2 		$41K Sell
4,389
-1,529
-26% -$15.5K ﹤0.01% 3189
2021
Q1 		$58K Sell
5,918
-4,962
-46% -$55.4K ﹤0.01% 2998
2020
Q4 		$111K Buy
10,880
+7,060
+185% +$71.5K ﹤0.01% 2244
2020
Q3 		$38K Sell
3,820
-124
-3% -$1.26K ﹤0.01% 3649
2020
Q2 		$41K Buy
+3,944
New +$40.8K ﹤0.01% 3207
2020
Q1 		– Sell
-17,378
Closed -$152K – 3669
2019
Q4 		$152K Buy
17,378
+15,325
+746% +$127K 0.01% 725
2019
Q3 		$22K Buy
+2,053
New +$22.2K ﹤0.01% 2420
2018
Q4 		– Sell
-1,132
Closed -$52K – 4217
2018
Q3 		$52K Buy
1,132
+989
+692% +$47.7K ﹤0.01% 1737
2018
Q2 		$8K Sell
143
-656
-82% -$38K ﹤0.01% 2888
2018
Q1 		$54K Buy
799
+661
+479% +$49.5K ﹤0.01% 1638
2017
Q4 		$14K Sell
138
-1,073
-89% -$120K ﹤0.01% 2333
2017
Q3 		$145K Buy
+1,211
New +$113K 0.01% 1016
2017
Q2 		– Sell
-91
Closed -$3K – 3245
2017
Q1 		$3K Sell
91
-6,566
-99% -$240K ﹤0.01% 2485
2016
Q4 		$204K Buy
6,657
+4,230
+174% +$183K 0.02% 620
2016
Q3 		$163K Buy
2,427
+1,740
+253% +$88K 0.02% 582
2016
Q2 		$20K Sell
687
-571
-45% -$17.9K ﹤0.01% 2233
2016
Q1 		$37K Buy
+1,258
New +$56.8K 0.01% 940
2015
Q3 		– Sell
-830
Closed -$97K – 4574
2015
Q2 		$97K Buy
830
+409
+97% +$74.1K 0.01% 873
2015
Q1 		$99K Sell
421
-79
-16% -$16.9K 0.01% 900
2014
Q4 		$95K Buy
+500
New +$111K 0.01% 705
2014
Q2 		– Sell
-2,050
Closed -$213K – 4482
2014
Q1 		$213K Buy
2,050
+1,850
+925% +$217K 0.03% 398
2013
Q4 		$21K Sell
200
-2,034
-91% -$119K ﹤0.01% 2286
2013
Q3 		$120K Buy
2,234
+2,131
+2,069% +$115K 0.01% 1131
2013
Q2 		$5K Buy
+103
New +$3.63K ﹤0.01% 2951

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Tower Research Capital (TRC)'s PBYI Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Puma Biotechnology (PBYI) stake by 15% in Q1 2026, buying an estimated $2.12K and bringing the position to 2,568 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3615.

Tower Research Capital (TRC) first reported a position in PBYI in Q2 2013 and has held it in 43 quarters since. The position peaked at $213K in Q1 2014. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Tower Research Capital (TRC) held 2,568 shares of Puma Biotechnology worth $16.4K as of Q1 2026.
  • Tower Research Capital (TRC) bought 329 Puma Biotechnology shares in Q1 2026, an estimated $2.12K.
  • Puma Biotechnology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3615 holding.
  • Tower Research Capital (TRC) first reported a position in Puma Biotechnology in Q2 2013 and has held it in 43 quarters since.
  • Tower Research Capital (TRC)'s Puma Biotechnology position peaked at $213K in Q1 2014.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.